FindTrial
Sign In

Factors influencing 17-hydroxyprogesterone levels in newborns

Maternal and Neonatal factors influencing 17-hydroxyprogesterone levels in newborns delivered at a tertiary care hospital

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/06/053673
Enrollment
428
Registered
2023-06-08
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E348- Other specified endocrine disorders

Interventions

Control Intervention1: NIL: NIL

Sponsors

Dr Shreya Anil Patted
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All Live Neonates born during the study period of one year of KLE Hospital,Belgaum

Exclusion criteria

Exclusion criteria: Lethal Congenital Anomalies

Design outcomes

Primary

MeasureTime frame
To study the maternal and neonatal factors influencing the serum 17- hydroxyprogesterone levels in newbornsTimepoint: 17- Hydroxyprogesterone levels between 72 completed hours of life and 7 days of life—

Secondary

MeasureTime frame
To estimate the recall rate using the current cut off levels of serum 17-hydroxyprogesterone levels in newbornsTimepoint: Maternal & neonatal factors affecting 17- hydroxyprogesterone levels from birth to 7 days of life—

Countries

India

Contacts

Public ContactDr Shreya Anil Patted
meenakshi.br@gmail.com9900184188

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026